news.today
Hello · Register today | LoginHello · My Account[—] [33]
World

Weight-loss drugs may affect cancer risk through immune changes

Summarised from 3 outlets · Updated 27 Sept, 11:48 · Archive

GLP-1 drugs like Ozempic and Wegovy may lower cancer risk by altering immune response.

GLP-1 weight-loss drugs such as Ozempic and Wegovy may play a role in cancer outcomes by altering the body's immune response, though researchers say key clinical trials are needed. The American Association for Cancer Research's 2026 Cancer Progress Report noted that obesity is a major risk factor for many cancers. The Mirror reports that nutritional support should play a critical role once treatment with a GLP-1 medication is initiated.

Weight-loss drugs may affect cancer risk through immune changes
Image: The Mirror

Comments (0)

How it is being reported

In this story: Ozempic · Wegovy · Liraglutide · American Association for Cancer Research

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log